ATE151418T1 - Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können - Google Patents

Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können

Info

Publication number
ATE151418T1
ATE151418T1 AT94903025T AT94903025T ATE151418T1 AT E151418 T1 ATE151418 T1 AT E151418T1 AT 94903025 T AT94903025 T AT 94903025T AT 94903025 T AT94903025 T AT 94903025T AT E151418 T1 ATE151418 T1 AT E151418T1
Authority
AT
Austria
Prior art keywords
pct
bind
carboxylic acid
acid derivatives
heterocyclic carboxylic
Prior art date
Application number
AT94903025T
Other languages
English (en)
Inventor
Hiroyuki Yoshimura
Mitsuo Nagai
Shigeki Hibi
Koichi Kikuchi
Ieharu Hishinuma
Junichi Nagakawa
Makoto Asada
Norimasa Miyamoto
Takayuki Hida
Aichi Ogasawara
Isao Yamatsu
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE151418T1 publication Critical patent/ATE151418T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
AT94903025T 1992-12-28 1993-12-20 Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können ATE151418T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP35861692 1992-12-28
JP2345093 1993-01-20
PCT/JP1993/001841 WO1994014777A1 (en) 1992-12-28 1993-12-20 Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)

Publications (1)

Publication Number Publication Date
ATE151418T1 true ATE151418T1 (de) 1997-04-15

Family

ID=26360806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903025T ATE151418T1 (de) 1992-12-28 1993-12-20 Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können

Country Status (14)

Country Link
US (1) US5612356A (de)
EP (1) EP0638071B1 (de)
JP (2) JP3476883B2 (de)
KR (2) KR0126300B1 (de)
CN (2) CN1036920C (de)
AT (1) ATE151418T1 (de)
CA (1) CA2129846A1 (de)
DE (1) DE69309670T2 (de)
DK (1) DK0638071T3 (de)
ES (1) ES2102195T3 (de)
FI (1) FI943948A0 (de)
GR (1) GR3024074T3 (de)
NO (1) NO304687B1 (de)
WO (1) WO1994014777A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US6716991B1 (en) 1993-11-30 2004-04-06 G. D. Searle & Co. Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
RU2139281C1 (ru) * 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
FR2735371B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes antagonistes des recepteurs rars
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6121309A (en) * 1996-03-18 2000-09-19 Eisai Co., Ltd. Fused-ring carboxylic acid derivatives
US5741896A (en) 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
JP2001518502A (ja) 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト チロシンキナーゼ活性を阻害するためのインデノ［１，２−ｃ］ピラゾール誘導体
ES2206997T3 (es) * 1997-10-06 2004-05-16 ABBOTT GMBH & CO. KG Derivados de indeno(1,2-c)-,de nafto(1,2-c),y de benzo(6,7)cicloepta(1,2-c)pirazol.
ATE334673T1 (de) * 1997-11-12 2006-08-15 Hoffmann La Roche Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
DE69909811T2 (de) * 1998-09-30 2004-01-29 Taisho Pharmaceutical Co Ltd Substituierte isoxazolylthiophenverbindungen
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
US6288099B1 (en) 1998-12-04 2001-09-11 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
WO2000061232A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
US6043381A (en) * 1999-05-07 2000-03-28 Allergan Sales, Inc. Process for preparing substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives
AU784377B2 (en) * 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
AU2002348469B2 (en) * 2001-10-18 2008-03-13 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7105566B2 (en) 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
WO2005040169A2 (en) 2003-09-17 2005-05-06 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as serotonin receptor modulators
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
DE602004019685D1 (de) 2003-12-26 2009-04-09 Allergan Inc DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
AU2006299645B2 (en) 2005-09-30 2011-02-03 Io Therapeutics, Llc Treatment of cancer with specific RXR agonists
JP2009537540A (ja) 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
WO2008124614A1 (en) 2007-04-06 2008-10-16 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
ES2534573T3 (es) 2007-04-06 2015-04-24 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
EP2845592A1 (de) * 2009-09-28 2015-03-11 F. Hoffmann-La Roche AG Benzoxazepin-PI3K-Hemmerverbindungen und Verfahren zur Verwendung
EP2483277B1 (de) * 2009-09-28 2015-12-02 F. Hoffmann-La Roche AG Benzoxazepin -pi3k-hemmerverbindungen und ihre verwendung
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
RU2013143747A (ru) 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
EP2909212B1 (de) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituierte 1,4-dihydropyrazolo[4,3-b]indole
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10239845B2 (en) 2015-02-02 2019-03-26 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
CN105061316B (zh) * 2015-07-17 2017-12-22 苏州大学 稠环类化合物、制备方法和用途
EP3368080B8 (de) 2015-10-31 2023-04-26 IO Therapeutics, Inc. Behandlung von erkrankungen des nervensystems mithilfe von kombinationen von rxr-agonisten und schilddrüsenhormonen
PL3380086T3 (pl) 2015-11-25 2022-02-21 Io Therapeutics, Inc. Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu
CN105418637A (zh) * 2015-12-08 2016-03-23 彭冬青 一种治疗甲亢的药物组合物
CN114904000A (zh) 2016-03-10 2022-08-16 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
DK3426303T3 (da) 2016-03-10 2022-09-19 Io Therapeutics Inc Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner
CA3026563C (en) 2016-06-10 2023-11-28 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
EP3472131B1 (de) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- und 6-hydroxamsäureindane als hdac-inhibitoren
CN109232591B (zh) * 2017-06-29 2021-02-02 广西师范大学 2,3-稠环吲哚啉生物碱及其合成方法和应用
EP3651757A4 (de) 2017-07-13 2021-08-25 IO Therapeutics, Inc. Rezeptorsubtyp und funktionsselektive retinoid- und rexinoidverbindungen in kombination mit immunmodulatoren zur krebsimmuntherapie
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3679012A1 (de) * 2017-09-07 2020-07-15 Taiwanj Pharmaceuticals Co., Ltd. Benzolkondensierte heterocyclische derivate und diese enthaltende pharmazeutische zusammensetzung
WO2019060600A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
AU2022407454A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3119819A (en) * 1959-07-29 1964-01-28 Ciba Geigy Corp Intermediates for 18-o-alkyl-reserpic acid esters and related compounds
GB1071124A (en) * 1965-05-11 1967-06-07 Biorex Laboratories Ltd Derivatives of pyrazolo-[4',5'-b]-11-oxo-18ª‡- and 18ª‰-olean-12-en-30-oic acid
FR2614618B1 (fr) * 1987-04-30 1989-07-07 Cird Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire
LU87040A1 (fr) * 1987-11-04 1989-06-14 Oreal Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative

Also Published As

Publication number Publication date
JP3476883B2 (ja) 2003-12-10
KR950700258A (ko) 1995-01-16
GR3024074T3 (en) 1997-10-31
FI943948A7 (fi) 1994-08-26
JP2004043482A (ja) 2004-02-12
DE69309670D1 (de) 1997-05-15
US5612356A (en) 1997-03-18
WO1994014777A1 (en) 1994-07-07
NO943165D0 (no) 1994-08-26
NO304687B1 (no) 1999-02-01
FI943948L (fi) 1994-08-26
ES2102195T3 (es) 1997-07-16
CN1173497A (zh) 1998-02-18
CN1094052A (zh) 1994-10-26
CN1036920C (zh) 1998-01-07
CA2129846A1 (en) 1994-07-07
DE69309670T2 (de) 1997-11-20
EP0638071B1 (de) 1997-04-09
FI943948A0 (fi) 1994-08-26
EP0638071A1 (de) 1995-02-15
NO943165L (no) 1994-10-25
KR0126300B1 (ko) 1997-12-26
DK0638071T3 (da) 1997-10-27
JP3992666B2 (ja) 2007-10-17
JPH06271545A (ja) 1994-09-27

Similar Documents

Publication Publication Date Title
ATE151418T1 (de) Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
GR3023635T3 (en) Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments.
BR1100412A (pt) Composto; método para propiciar tratamento imunomodulador; e composição farmacêutica para tratamento imunomodulador
ZA952614B (en) The use of carboxylic acid derivatives as drugs
DE69510338D1 (de) Azirdin-derivate, deren herstellung und verwendung
ES2138092T3 (es) Utilizacion de los derivados de carbostirilo para la obtencion de un medicamento destinado para inhibir la produccion de la interleucina-8.
SE8102220L (sv) Anvendning av substituerade derivat av 4-fenyl-4-oxo-2-butensyra sasom lekemedel
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
ATE161178T1 (de) Pyrazolpyridine für die behandlung der anämie
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
DK0646110T3 (da) N-substituerede 3-azabicyclo(3.2.0) heptanderivater som neuroleptika
IL108288A0 (en) Pyrrolidine derivatives, their preparation and medicaments containing them
FI933925A0 (fi) N-((4,5-dihydroxi- och 4,5,8-trihydroxi-9,10-dihydro-9,10-dioxo-2-antracenyl)karbonyl)aminosyror, vilka aer anvaendbara foer vaord av benledsjukdomar
EP0001715A3 (de) Azetidinon Antibiotika und ihre pharmazeutischen Präparate und Verwendung
IL108290A0 (en) Pyrrolidine derivatives, their preparation and medicaments containing them
KR970701188A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ACE)의 억제제로서 유용한 신규의 머캅토아세틸아미드 디설파이드 유도체(Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ACE)
HUT68806A (en) Isoxazole carboxylic acid amides, process for producing them and their use
PL1637537T3 (pl) Nowe leki

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee